Coya Therapeutics stock maintains Buy rating as Phase 2 ALS trial begins
PositiveFinancial Markets

Coya Therapeutics has received a Buy rating as it embarks on its Phase 2 trial for ALS, a significant step in the fight against this challenging disease. This trial is crucial as it could pave the way for new treatment options for patients suffering from ALS, which currently has limited effective therapies. Investors are optimistic about the potential outcomes, making this a noteworthy development in the biotech sector.
— Curated by the World Pulse Now AI Editorial System